Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rezolute (RZLT) Asset Writedowns and Impairment (2018 - 2020)

Rezolute recorded quarterly Asset Writedowns and Impairment of $23000.0 in Q2 2020, up 91.67% quarter-over-quarter from $12000.0 in Q2 2019, and up 91.67% year-over-year from $12000.0 in Q3 2019.

Rezolute's Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $23000.0 for Q2 2020.

  • In Q2 2020, Asset Writedowns and Impairment rose 91.67% year-over-year to $23000.0; the TTM figure through Jun 2020 stood at $35000.0 (down 97.98% YoY), while the FY2020 annual figure was $23000.0, down 48.89% from the prior year.
  • Asset Writedowns and Impairment came in at $23000.0 for Q2 2020 at Rezolute, up from $12000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $1.7 million in Q2 2018 to a low of $12000.0 in Q2 2019.
  • A 3-year average of $439750.0 and a median of $28000.0 in 2018 frame the typical range for Asset Writedowns and Impairment.
  • Across the five-year window, Asset Writedowns and Impairment plunged 99.29% in 2019 and surged 91.67% in 2020, its largest moves.
  • Rezolute's Asset Writedowns and Impairment stood at $33000.0 in 2018, then tumbled by 63.64% to $12000.0 in 2019, then jumped by 91.67% to $23000.0 in 2020.
  • According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $23000.0, $12000.0, and $33000.0 for Q2 2020, Q2 2019, and Q4 2018 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Rezolute 374.41 Mn 374.41 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2020 23,000.00
Jun 30, 2020 23,000.00
Jun 30, 2019 12,000.00
Jun 30, 2019 12,000.00
Dec 31, 2018 33,000.00
Dec 31, 2018 33,000.00
Jun 30, 2018 1.69 Mn
Jun 30, 2018 1.69 Mn